$-1.55
(Market cap
$6 Mln
Recently Viewed
Clear AllMarket cap
$6 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
1.3
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-- Mln
ROE
-7.3 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-5
Debt to Equity
--
Book Value
$--
EPS
$-9.3
Face value
--
Shares outstanding
9,799,538
CFO
$-198.25 Mln
EBITDA
$-232.15 Mln
Net Profit
$-259.32 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Orgenesis (ORGS)
| -- | -- | -- | -- | -66.9 | -61.5 | -35.8 |
|
BSE Sensex
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Orgenesis (ORGS)
| -74.4 | -32.3 | -36.0 | -3.4 | -0.4 | -18.6 | 54.7 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Orgenesis (ORGS)
|
0.4 | 5.7 | 1.0 | -48.2 | -- | 164.7 | -- | 1.3 |
| 8.0 | 5,530.3 | 6,552.2 | -551.4 | -6.1 | -9.9 | -- | 1.0 | |
| 299.5 | 8,082.3 | 2,589.9 | 168.8 | 21.4 | 2.5 | 49.7 | 1.1 | |
| 36.8 | 5,219.7 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.2 | |
| 140.2 | 8,408.6 | 551.4 | -189.3 | -15.6 | -26.3 | -- | 12.5 | |
| 85.5 | 5,284.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 23.8 | 4.9 | |
| 178.5 | 9,344.7 | 1,526.9 | -151.5 | 20.0 | -17.1 | 46.5 | 13.0 | |
| 325.3 | 12,840.9 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.4 | 9.0 | |
| 117.2 | 6,379.3 | 738.3 | 48.9 | 11.4 | 2.4 | 131.5 | 3.1 | |
| 31.2 | 13,200.5 | 6,178.4 | 626.5 | 13.0 | 11.9 | 21.6 | 2.5 |
Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments: Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell... based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model, POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. It also provides hospital services and cell process development services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland. Read more
Chairperson of the Board, CEO & President
Ms. Vered Caplan M.Sc.
Chairperson of the Board, CEO & President
Ms. Vered Caplan M.Sc.
Headquarters
Germantown, MD
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Orgenesis Inc (ORGS) is $0.40 (NASDAQ) as of 30-Apr-2026 09:30 EDT. Orgenesis Inc (ORGS) has given a return of -66.87% in the last 3 years.
Since, TTM earnings of Orgenesis Inc (ORGS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
-0.29
|
-0.75
|
|
2023
|
--
|
--
|
|
2022
|
-3.35
|
1.81
|
|
2022
|
--
|
--
|
The 52-week high and low of Orgenesis Inc (ORGS) are Rs 2.25 and Rs 0.05 as of 02-May-2026.
Orgenesis Inc (ORGS) has a market capitalisation of $ 6 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Orgenesis Inc (ORGS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.